Genome-Wide Mendelian Randomization Identifies Ferroptosis-Related Drug Targets for Alzheimer’s Disease
Journal of Alzheimer's Disease Reports · 09.01.2024 · 8 (1) · 1185-1197
DOI: 10.3233/adr-240062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease Reports, online erschienen am 05.09.2024. Verfasst von Ying Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Traditional Chinese and Western Medicine Hospital of Wuhan/Wuhan First Hospital, Tongji Medical College, Huazhong University…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background
Alzheimer’s disease (AD) currently lacks effective disease-modifying treatments. Recent research suggests that ferroptosis could be a potential therapeutic target. Mendelian randomization (MR) is a widely used method for identifying novel therapeutic targets.
Objective
Employ genetic information to evaluate the causal impact of ferroptosis-related genes on the risk of AD.
Methods
564 ferroptosis-related genes were obtained from FerrDb. We derived genetic instrumental variables for these genes using four brain quantitative trait loci (QTL) and two blood QTL datasets. Summary-data-based Mendelian randomization (SMR) and two-sample MR methods were applied to estimate the causal effects of ferroptosis-related genes on AD. Using extern transcriptomic datasets and triple-transgenic mouse model of AD (3xTg-AD) to further validate the gene targets identified by the MR analysis.
Results
We identified 17 potential AD risk gene targets from GTEx, 13 from PsychENCODE, and 22 from BrainMeta (SMR p < 0.05 and HEIDI test p > 0.05). Six overlapping ferroptosis-related genes associated with AD were identified, which could serve as potential therapeutic targets (PEX10, CDC25A, EGFR, DLD, LIG3, and TRIB3). Additionally, we further pinpointed risk genes or proteins at the blood tissue and pQTL levels. Notably, EGFR demonstrated significant dysregulation in the extern transcriptomic datasets and 3xTg-AD models.
Conclusions
This study provides genetic evidence supporting the potential therapeutic benefits of targeting the six druggable genes for AD treatment, especially for EGFR (validated by transcriptome and 3xTg-AD), which could be useful for prioritizing AD drug development in the field of ferroptosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Traditional Chinese and Western Medicine Hospital of Wuhan/Wuhan First Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Neurology, Wuhan First Hospital, Hubei University of Chinese Medicine, Wuhan, China.
- Department of Neurology, Traditional Chinese and Western Medicine Hospital of Wuhan, Hubei University of Chinese Medicine, Wuhan, China.
Zitieren
APA
Wang, Y., Song, X., Wang, R., Xu, X., Du, Y., Chen, G., & Mei, J. (2024). Genome-Wide Mendelian Randomization Identifies Ferroptosis-Related Drug Targets for Alzheimer’s Disease. Journal of Alzheimer's Disease Reports, 8(1), 1185-1197. https://doi.org/10.3233/adr-240062
Vancouver
Wang Y, Song X, Wang R, Xu X, Du Y, Chen G, et al. Genome-Wide Mendelian Randomization Identifies Ferroptosis-Related Drug Targets for Alzheimer’s Disease. Journal of Alzheimer's Disease Reports. 2024;8(1):1185-1197. doi:10.3233/adr-240062
BibTeX
@article{Wang2024,
author = {Wang, Ying and Song, Xinhua and Wang, Rui and Xu, Xinzi and Du, Yaming and Chen, Guohua and Mei, Junhua},
title = {Genome-Wide Mendelian Randomization Identifies Ferroptosis-Related Drug Targets for Alzheimer’s Disease},
journal = {Journal of Alzheimer's Disease Reports},
year = {2024},
volume = {8},
number = {1},
pages = {1185--1197},
doi = {10.3233/adr-240062}
}
EUVIMED